Success Metrics

Clinical Success Rate
80.6%

Based on 54 completed trials

Completion Rate
81%(54/67)
Active Trials
28(20%)
Results Posted
15%(8 trials)
Terminated
13(9%)

Phase Distribution

Ph phase_4
2
1%
Ph phase_1
6
4%
Ph early_phase_1
3
2%
Ph not_applicable
73
53%
Ph phase_2
8
6%
Ph phase_3
2
1%

Phase Distribution

9

Early Stage

8

Mid Stage

4

Late Stage

Phase Distribution94 total trials
Early Phase 1First-in-human
3(3.2%)
Phase 1Safety & dosage
6(6.4%)
Phase 2Efficacy & side effects
8(8.5%)
Phase 3Large-scale testing
2(2.1%)
Phase 4Post-market surveillance
2(2.1%)
N/ANon-phased studies
73(77.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

72.0%

54 of 75 finished

Non-Completion Rate

28.0%

21 ended early

Currently Active

28

trials recruiting

Total Trials

139

all time

Status Distribution
Active(36)
Completed(54)
Terminated(21)
Other(28)

Detailed Status

Completed54
unknown28
Recruiting27
Terminated13
Withdrawn8
Not yet recruiting7

Development Timeline

Analytics

Development Status

Total Trials
139
Active
28
Success Rate
80.6%
Most Advanced
Phase 4

Trials by Phase

Early Phase 13 (3.2%)
Phase 16 (6.4%)
Phase 28 (8.5%)
Phase 32 (2.1%)
Phase 42 (2.1%)
N/A73 (77.7%)

Trials by Status

not_yet_recruiting75%
recruiting2719%
terminated139%
withdrawn86%
active_not_recruiting11%
enrolling_by_invitation11%
unknown2820%
completed5439%

Recent Activity

Clinical Trials (139)

Showing 20 of 139 trialsScroll for more
NCT05036707Phase 1

Human Immune Response to Ixodes Scapularis Tick Bites

Recruiting
NCT07474779Not Applicable

Understanding Alpha-Synuclein Spread in Parkinson's Disease Through Blood Biomarkers and Neuroimaging

Not Yet Recruiting
NCT02530658

Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients

Recruiting
NCT05660421Phase 2

Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors

Withdrawn
NCT02320656Not Applicable

Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015

Completed
NCT07539454Phase 2

Nirogacestat in Patients With Kaposi Sarcoma

Not Yet Recruiting
NCT05747937Not Applicable

Longitudinal Assessment of Autonomic and Sensory Nervous System in ALS

Recruiting
NCT07349771Phase 2

Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial

Not Yet Recruiting
NCT07011810Phase 2

Axatilimab for Sclerotic Chronic Graft-versus-Host Disease

Recruiting
NCT01208792Not Applicable

Auto-immunity and Pulmonary Arterial Hypertension

Completed
NCT05996731Not Applicable

Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases

Recruiting
NCT03958747Not Applicable

Ultrasound for the Detection of Oxaliplatin-Induced Peripheral Neuropathy

Completed
NCT06812702

Parkinson's Disease Biomarker Study

Completed
NCT04590209Not Applicable

Clinical and Mechanistic Study of Patients (With COVID-19 or Not) With a Recent Acrosyndrome

Withdrawn
NCT05394506Not Applicable

Modifying Factors in Striated Muscle Laminopathies

Recruiting
NCT05890781Not Applicable

Engineering Immune Organoids to Study Pediatric Cancer

Recruiting
NCT06050330Not Applicable

CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study

Completed
NCT05739149Not Applicable

A Study to Evaluate Microvessel Ultrasound Imaging of Wound Healing in Patients With Chronic Ulcers

Recruiting
NCT02061254Not Applicable

Transient Elastography DEdicated to Cosmetology And Dermatology (TEDECAD)

Completed
NCT03559465Not Applicable

Profibrosing Role of B Lymphocytes in Patients With Systemic Sclerosis.

Completed

Drug Details

Intervention Type
PROCEDURE
Total Trials
139